117 KENDRICK STREET, NEEDHAM, MA
Market cap: $383.8M (2/10/2026)
Price: $6.34
Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers
Delivering Novel Therapies for RAS/MAPK Pathway - Driven Cancers PRESENTATION JANUARY 2026
Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
Announces Strategic Transition Plan to Accelerate Next Phase of Growth
PART II INFORMATION NOT REQUIRED IN PROSPECTUS
Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates
Verastem Oncology Reports Positive Preliminary Results from VS-7375 Trial in KRAS G12D Mutant Solid Tumors
Updated Data on GFH375 for KRAS G12D Mutant Pancreatic Cancer by Verastem Oncology and GenFleet
Q2
Q1
Q3
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Free Writing Prospectus